文献リスト

1) 日本循環器学会・循環器病の診断と治療に関するガイドライン作成班(班長: 尾崎承一). 血管炎症候群の診療ガイドライン. Circ J. 2008; 72 Supplement IV: 1253-318. http://www.j-circ.or.jp/guideline/pdf/JCS2008_ozaki_h.pdf

2) Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009; 68: 318-23

3) Mukhtyar C, Guillevin L, Cid MC, et al, EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009; 68: 310-7

4) Ito I. Medical treatment of Takayasu arteritis. Heart Vessels Suppl. 1992; 7: 133-7

5) Moriwaki R, Numano F. Takayasu arteritis: follow-up studies for 20 years. Heart Vessels Suppl. 1992; 7: 138-45

6) Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasuʼs arteritis and its therapy. Ann Intern Med. 1985; 103: 121-6

7) Maksimowicz KM, Clark TM, Hoffman GS. Limitations of thrapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007; 56: 1000-9

8) Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994; 37: 578-82

9) Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasuʼs arteritis. J Rheumatol. 2003; 30: 1793-8

10) Fearfield LA, Ross JR, Farrell AM, et al. Pyoderma gangrenosum associated with Takayasuʼs arteritis responding to cyclosporin. Br J Dermatol. 1999; 141: 339-43

11) Ujiie H, Sawamura D, Yokota K, et al. Pyoderma gangrenosum associated with Takayasuʼs arteritis. Clin Exp Dermatol. 2004; 29: 357-9

12) Shinjo SK, Pereira RM, Tizziani VA, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007; 26: 1871-5

13) Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004; 50: 2296-304

14) Voltarelli JC, Oliveira MC, Stracieri AB, et al. Haematopoietic stem cell transplantation for refractory Takayasuʼs arteritis. Rheumatology (Oxford). 2004; 43: 1308-9

15) Makino N, Orita Y, Takeshita A, et al. Coronary arterial involvement in Takayasuʼs disease. Jpn Heart J. 1982; 23: 1007-13

16) Tada Y, Sato O, Ohshima A, et al. Surgical treatment of Takayasu arteritis. Heart Vessels Suppl. 1992; 7: 159-67

17) Sasaki S, Kubota S, Kunihara T, et al. Surgical experience of the thoracic aortic aneurysm due to Takayasuʼs arteritis. Int J Cardiol. 2000; 75 Suppl 1: S129-34

18) Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005; 17: 16-24

19) Parra JR, Perler BA. Takayasuʼs disease. Semin Vasc Surg. 2003; 16: 200-8

20) Taketani T, Miyata T, Morota T, et al. Surgical treatment of atypical aortic coarctation complicating Takayasuʼs arteritis--experience with 33 cases over 44 years. J Vasc Surg. 2005; 41: 597-601

21) Kumar A, Dubey D, Bansal P, et al. Surgical and radiological management of renovascular hypertension in a developing country. J Urol. 2003; 170: 727-30

22) Weaver FA, Kumar SR, Yellin AE, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg. 2004; 39: 749-57

23) Vanoli M, Daina E, Salvarani C, et al. Takayasuʼs arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005; 53: 100-7

24) Park MC, Lee SW, Park YB, et al. Clinical characteristics and outcomes of Takayasuʼs arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005; 34: 284-92

25) Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002; 46: 1634-42

26) Choe YH, Han BK, Koh EM, et al. Takayasuʼs arteritis: assessment of disease activity with contrast-enhanced MR imaging. AJR Am J Roentgenol. 2000; 175: 505-11

27) Webb M, Chambers A, A AL-N, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004; 31: 627-34

28) Teoh MK. Takayasuʼs arteritis with renovascular hypertension: results of surgical treatment. Cardiovasc Surg. 1999; 7: 626-32

29) Matsuura K, Ogino H, Matsuda H, et al. Surgical outcome of aortic arch repair for patients with Takayasu arteritis. Ann Thorac Surg. 2006; 81: 178-82

30) Fields CE, Bower TC, Cooper LT, et al. Takayasuʼs arteritis: operative results and influence of disease activity. J Vasc Surg. 2006; 43: 64-71

31) Giordano JM, Leavitt RY, Hoffman G, et al. Experience with surgical treatment of Takayasuʼs disease. Surgery. 1991; 109: 252-8

32) Lacombe M, Ricco JB. Surgical revascularization of renal artery after complicated or ailed percutaneous transluminal renal angioplasty. J Vasc Surg. 2006; 44: 537-44

33) Min PK, Park S, Jung JH, et al. Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasuʼs arteritis. J Endovasc Ther. 2005; 12: 28-34

34) Sharma BK, Jain S, Bali HK, et al. A follow-up study of balloon angioplasty and denovo stenting in Takayasu arteritis. Int J Cardiol. 2000; 75 Suppl 1: S147-52

35) Ando M, Kosakai Y, Okita Y, et al. Surgical treatment for aortic regurgitation caused by Takayasuʼs arteritis. J Card Surg. 1998; 13: 202-7

36) Miyata T, Sato O, Koyama H, et al. Long-term survival after surgical treatment of patients with Takayasuʼs arteritis. Circulation. 2003; 108: 1474-80

37) Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33: 1122-8

38) Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol. 2004; 16: 25-30

39) Dasgupta B, Hassan N. Giant cell arteritis: recent advances and guidelines for management. Clin Exp Rheumatol. 2007; 25(1 Suppl 44): S62-5

40) Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000; 27: 1484-91

41) Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006; 54: 3310-8

42) Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002; 46: 1309-18

43) Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 134: 106-14

44) Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001; 19: 495-501

45) Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004; 50: 1332-7

46) Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003; 62: 373-4

47) Airo P, Antonioli CM, Vianelli M, et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford). 2002; 41: 347-9

48) Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001; 44: 2933-5

49) Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocortico-steroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007; 146: 621-30

50) Varma D, OʼNeill D. Quantification of the role of temporal artery biopsy in diagnosing clinically suspected giant cell arteritis. Eye. 2004; 18: 384-8

51) Younge BR, Cook BE Jr, Bartley GB, et al. Initiation of glucocorticoid therapy: before or after temporal artery biopsy？ Mayo Clin Proc. 2004; 79: 483-91

52) Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999; 128: 211-5

53) Pless M, Rizzo JF 3rd, Lamkin JC, et al. Concordance of bilateral temporal artery biopsy in giant cell arteritis. J Neuroophthalmol. 2000; 20: 216-8

54) Mahr A, Saba M, Kambouchner M, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better？ Ann Rheum Dis. 2006; 65: 826-8

55) Sharma NS, Ooi JL, McGarity BH, et al. The length of superficial temporal artery biopsies. ANZ J Surg. 2007; 77: 437-9

56) Lenton J, Donnelly R, Nash JR. Does temporal artery biopsy influence the management of temporal arteritis？ QJM. 2006; 99: 33-6

57) Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology. 2005; 112: 1098-103

58) Narvaez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007; 37: 13-9

59) Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005; 142: 359-69

60) Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003; 49: 703-8

61) Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003; 110: 539-42

62) Cortet B, Hachulla E, Barton I, et al. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev Rhum Engl Ed. 1999; 66: 214-9

63) Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007; 56: 2789-97

64) Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006; 113: 1842-5

65) Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005; 84: 269-76

66) Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003; 48: 3522-31

67) Ray JG, Mamdani MM, Geerts WH. Giant cell arteritis and cardiovascular disease in older adults. Heart. 2005; 91: 324-8

68) Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006; 54: 3306-9

69) Narvaez J, Bernad B, Nolla JM, et al. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum. 2007; 36: 322-7

70) Garcia-Martinez A, Hernandez-Rodriguez J, Grau JM, et al. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004; 51: 674-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp